Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Similarly, Vitamin D deficiency (OR 1.13; 95% CI = 0.54 to 2.37), elevated homocysteine levels (OR 2.05; 95% CI = 0.78 to 5.41), and folic acid deficiency (OR 1.27; 95% CI = 0.48 to 3.31) showed higher odds without statistical significance (Table 4).

Source: Determinants for Impaired BMD. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This cross‐sectional study includes WT survivors treated between 1963 and 2002, recruited as part of the DCCSS‐LATER cohort between 2016 and 2020.

Source: Abstract.

Patients were recruited between 2016 and 2020 and were eligible for inclusion if they had been diagnosed before the age of 19, had survived for more than five years after diagnosis, and were aged between 18 and 45 years at the time of this study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prevalence and Determinants of Impaired Bone Mineral Density and Fractures in the First National Dutch Wilms Tumor Survivor Cohort, a National DCCSS‐LATER Study

Cross-sectional study · Cancer Medicine · 2025

Original publication title

Prevalence and Determinants of Impaired Bone Mineral Density and Fractures in the First National Dutch Wilms Tumor Survivor Cohort, a National DCCSS‐LATER Study

Francis S. P. L. Wens; Demi T. C. de Winter; Geert O. Janssens; Rens Litjens; Jenneke E. van Atteveld; Rutger A. J. Nievelstein; Monique G. G. Hobbelink; Andrica C. H. de Vries; Jacqueline J. Loonen; Eline van Dulmen‐den Broeder; Helena J. H. van der Pal; Saskia M. F. Pluijm; Leontien C. M. Kremer; Margriet van der Heiden‐van der Loo; Marloes Louwerens; Hanneke M. van Santen; Daniel S. Olsson; Imo Hoefer; Sjoerd A. A. van den Berg; Harm van Tinteren; Sebastian J. C. M. M. Neggers; Marry M. van den Heuvel‐Eibrink

© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Wilms tumor survivors treated with ≥ 4 drugs or abdominal radiotherapy (> 30 Gy) seem to be at increased risk of impaired BMD; this could indicate the need for surveillance for this subset of Wilms tumor survivors exposed to these treatment regimens in the past.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Wilms tumors (WT) are the most common kidney tumors in children, with excellent survival rates (90%). However, late adverse effects warrant attention. Limited data exist on musculoskeletal sequelae in WT survivors. We aimed to assess the prevalence and determinants of impaired bone mineral density (BMD) and fractures in a national cohort of Dutch WT survivors.

Source: Background

Abstract: What methods does the paper describe?

This cross‐sectional study includes WT survivors treated between 1963 and 2002, recruited as part of the DCCSS‐LATER cohort between 2016 and 2020. Dual‐energy X‐ray absorptiometry (DXA) scans were used to assess BMD. Low BMD was defined as a Z‐score ≤ 1. From 5 years after diagnosis, fracture prevalence was assessed by questionnaires. Univariable logistic regression was used to analyze associations between impaired BMD as well as fractures with independent variables like patient characteristics, treatments, comorbidities, and lifestyle‐related factors.

Source: Method

Abstract: Results

Of 437 invited kidney tumor survivors, 233 WT survivors participated (median age 32.1 years, median follow‐up 27.8 years). DXA scans and fracture data were available for 173 and 221 WT survivors, respectively. Low BMD at any site was observed in 26% (n = 46/173) of survivors and was significantly associated with treatment including ≥ 4 drugs (OR 2.76; 95% CI = 1.13 to 6.70). Abdominal radiotherapy doses > 30 Gy (OR 4.84; 95% CI = 1.06 to 22.2) were significantly associated with low lumbar spine BMD.

The prevalence of fragility fractures was 16.3% (n = 36/221). The standardized incidence ratio (SIR) of any first fracture was 2.34 for males and 5.38 for females.

Source: Results

Abstract: Conclusion

Wilms tumor survivors treated with ≥ 4 drugs or abdominal radiotherapy (> 30 Gy) seem to be at increased risk of impaired BMD; this could indicate the need for surveillance for this subset of Wilms tumor survivors exposed to these treatment regimens in the past.

Source: Conclusion
Authors’ abstract

ABSTRACT

Background

Wilms tumors (WT) are the most common kidney tumors in children, with excellent survival rates (90%). However, late adverse effects warrant attention. Limited data exist on musculoskeletal sequelae in WT survivors. We aimed to assess the prevalence and determinants of impaired bone mineral density (BMD) and fractures in a national cohort of Dutch WT survivors.

Method

This cross‐sectional study includes WT survivors treated between 1963 and 2002, recruited as part of the DCCSS‐LATER cohort between 2016 and 2020. Dual‐energy X‐ray absorptiometry (DXA) scans were used to assess BMD. Low BMD was defined as a Z‐score ≤ 1. From 5 years after diagnosis, fracture prevalence was assessed by questionnaires. Univariable logistic regression was used to analyze associations between impaired BMD as well as fractures with independent variables like patient characteristics, treatments, comorbidities, and lifestyle‐related factors.

Results

Of 437 invited kidney tumor survivors, 233 WT survivors participated (median age 32.1 years, median follow‐up 27.8 years). DXA scans and fracture data were available for 173 and 221 WT survivors, respectively. Low BMD at any site was observed in 26% (n = 46/173) of survivors and was significantly associated with treatment including ≥ 4 drugs (OR 2.76; 95% CI = 1.13 to 6.70). Abdominal radiotherapy doses > 30 Gy (OR 4.84; 95% CI = 1.06 to 22.2) were significantly associated with low lumbar spine BMD.

The prevalence of fragility fractures was 16.3% (n = 36/221). The standardized incidence ratio (SIR) of any first fracture was 2.34 for males and 5.38 for females.

Conclusion

Wilms tumor survivors treated with ≥ 4 drugs or abdominal radiotherapy (> 30 Gy) seem to be at increased risk of impaired BMD; this could indicate the need for surveillance for this subset of Wilms tumor survivors exposed to these treatment regimens in the past.

Publication and source details

Original title: Prevalence and Determinants of Impaired Bone Mineral Density and Fractures in the First National Dutch Wilms Tumor Survivor Cohort, a National DCCSS‐LATER Study

Francis S. P. L. Wens; Demi T. C. de Winter; Geert O. Janssens; Rens Litjens; Jenneke E. van Atteveld; Rutger A. J. Nievelstein; Monique G. G. Hobbelink; Andrica C. H. de Vries; Jacqueline J. Loonen; Eline van Dulmen‐den Broeder; Helena J. H. van der Pal; Saskia M. F. Pluijm; Leontien C. M. Kremer; Margriet van der Heiden‐van der Loo; Marloes Louwerens; Hanneke M. van Santen; Daniel S. Olsson; Imo Hoefer; Sjoerd A. A. van den Berg; Harm van Tinteren; Sebastian J. C. M. M. Neggers; Marry M. van den Heuvel‐Eibrink

Cancer Medicine · 2025

* Correspondence:
Marry M. van den Heuvel‐Eibrink (m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl)
© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Stichting Kinderen Kankervrij10.13039/501100006244 Maarten van der Weijden Foundation 463

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:08:29.201115+00:00

DOI: 10.1002/cam4.71229 · PMC12438959